Real World Evidence from a Retrospective Multi-Center Analysis for Ipilimumab and Nivolumab (I/N) As First-Line Treatment in Patients with Advanced Renal Cell Carcinoma in Different IMDC Risk Categories
ONCOLOGY RESEARCH AND TREATMENT(2024)
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined